Neurocrine Biosciences, Inc.NBIXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
29.40%
↓ 13% below average
Average (9y)
33.60%
Historical baseline
Range
High:75.53%
Low:-2.61%
CAGR
-10.0%
Structural decline
| Period | Value |
|---|---|
| 2024 | 29.40% |
| 2023 | 21.82% |
| 2022 | 41.36% |
| 2021 | 19.31% |
| 2020 | 37.50% |
| 2019 | 28.37% |
| 2018 | 69.67% |
| 2017 | -2.61% |
| 2016 | 15.71% |
| 2015 | 75.53% |